公开(公告)号：KR1020120026874A

公开(公告)日：2012-03-20

申请号：KR1020100089049

申请日：2010-09-10

Applicant: 서울대학교산학협력단

Inventor： 전주홍 ,  서인석 ,  김수화

IPC: A61K31/215 ,  A61K31/185 ,  A61P35/00

Abstract: PURPOSE: A pharmaceutical composition for preventing or treating hormone refractory prostate cancer and a method for screening the same are provided to ensure remarkable anticancer effect. CONSTITUTION: A pharmaceutical composition for preventing or treating hormone refractory prostate cancer contains a compound of chemical formula 1 or 2, pharmaceutically acceptable salt thereof, solvate, or hydrate thereof. The composition induces hormone refractory prostate cancer cell death through apoptosis and autophage pathway. A composition for chemosensitizer for hormone refractory prostate cancer contains the compound of chemical formula 1 or 2, pharmaceutically acceptable salt thereof, solvate, or hydrate thereof. A method for screening a therapeutic agent for cancer comprises: a step of treating test materials to cells which expresses E2F1(E2F transcription factor 1); and a step of analyzing expression or activation of E2F1 in the cells.

Abstract translation: 目的：提供用于预防或治疗激素难治性前列腺癌的药物组合物及其筛选方法，以确保显着的抗癌作用。 构成：用于预防或治疗激素难治性前列腺癌的药物组合物含有化学式1或2的化合物，其药学上可接受的盐，溶剂化物或其水合物。 该组合物通过凋亡和自噬途径诱导激素难治性前列腺癌细胞死亡。 用于激素难治性前列腺癌的化学敏化剂的组合物含有化学式1或2的化合物，其药学上可接受的盐，溶剂化物或其水合物。 筛选癌症治疗剂的方法包括：将试验材料处理至表达E2F1（E2F转录因子1）的细胞的步骤; 以及分析细胞中E2F1的表达或活化的步骤。

公开(公告)号：KR101207981B1

公开(公告)日：2012-12-04

申请号：KR1020100089049

申请日：2010-09-10

Applicant: 서울대학교산학협력단

Inventor： 전주홍 ,  서인석 ,  김수화

IPC: A61K31/215 ,  A61K31/185 ,  A61P35/00

Abstract: 본발명은호르몬불응성전립선암의예방또는치료용약제학적조성물및 그의스크리닝방법에관한것이다. 본발명의조성물은호르몬불응성전립선암에대한현저한항암효능이있고, 다른화학항암제와관련하여화학감작제로서도뛰어난효능을나타낸다. 또한본 발명의스크리닝방법은새로이규명한항암메카니즘을통해항암물질을정확하고쉽게동정할수 있다.